ANNOVIS BIO INC

NYSE: ANVS (Annovis Bio, Inc.)

Last update: 12 Nov, 3:22AM

0.853

-0.02 (-2.40%)

Previous Close 0.874
Volume 1,613,619
Price / Book 16.34
52 Weeks Range
0.620 (-27%) — 5.50 (544%)
Diluted EPS (TTM) -2.24
Current Ratio (MRQ) 10.68
Operating Cash Flow (TTM) -22.96 M
Levered Free Cash Flow (TTM) -13.95 M
Return on Assets (TTM) -91.05%
Return on Equity (TTM) -280.78%

AIStockmoo Score

-1.4
Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Downtrend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Insiders net buying recently. info
Institutional Flow info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Short-term momentum falling. info
Price is near support. info
Final Score -1.42
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Annovis Bio, Inc. Mixed Mixed

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
ANVS - - - 16.34 -1.4
ADCT - - - - -1.3
DNA - - - 1.68 1.2
ANRO - - - 4.13 0.0
RCUS - - - 6.21 -1.8
NUVB - - - 6.18 -1.1

Select this tab to load the latest available analysis.

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 14.69%
% Held by Institutions 16.09%

Ownership

Name Date Shares Held
Empery Asset Management, Lp 30 Jun 2026 2,401,476

No data within this time range.

Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
HOFFMAN MICHAEL B 0.840 - 5,000,000 4,200,000
Aggregate Net Quantity 5,000,000
Aggregate Net Value ($) 4,200,000
Aggregate Avg. Buy ($) 0.840
Aggregate Avg. Sell ($) -
Name Holder Date Type Quantity Price Value ($)
HOFFMAN MICHAEL B Director 06 Nov 2026 Buy (+) 5,000,000 0.840 4,200,000
0 Positive 0 Negative 2 Neutral
Date Type Details
09 Nov 2026 Yahoo Finance Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through the pivotal Phase 3 Alzheimer’s data readout in March 2027 MALVERN, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the…
04 Nov 2026 Yahoo Finance Annovis Announces Launch of Proposed Public Offering
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s…
30 Oct 2026 Yahoo Finance Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's…
29 Oct 2026 Yahoo Finance Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updatesMALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational…
22 Oct 2026 Yahoo Finance Annovis to Attend the CTAD 2026 with Three Presentations
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s…
06 Oct 2026 Yahoo Finance Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
Recently published Parkinson's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets…
23 Sep 2026 Yahoo Finance Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s…
08 Sep 2026 Yahoo Finance Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
02 Sep 2026 Yahoo Finance Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
Annovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements…
25 Aug 2026 Yahoo Finance Annovis to Host Corporate Update Webinar on September 2, 2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s…

Technical Setup Medium

Trend order
Slope
Entry
Volume
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days.
Nearest support: 0.586 – 0.655 · moderate level
Nearest resistance: 0.896 – 1.085 · strong level · tested often, may give way

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria